Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAA-IPC 2011-003 busulfan + fludarabine + thymoglobuline dosing in allogeneic SCT for high-risk myeloid malignancies
2024-516435-27-00Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of busulfan in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and myeloid diseases (3 arms), sponsored by Institut Paoli-Calmettes. Primary endpoint: Time to progression or death. Started Nov 2024; status: completed.
02
Drugs
busulfan
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)myeloid diseases
Beyond the preview
Go deeper on 2024-516435-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516435-27-00.